Developer docs
API playgroundTry for free, no card

Search company profiles

RapidAI

Full company profile

uuid000057y

Namestring
RapidAI
Legal namestring
iSchemaView, Inc.
Websiteurl
rapidai.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

RapidAI (legal entity iSchemaView, Inc.) is a privately held clinical AI company that develops FDA-cleared imaging software for stroke, neurovascular, and cardiovascular care. Its Rapid Enterprise Platform bundles 30 cleared modules — including Rapid CTP, Rapid LVO/LMVO, Rapid ICH, Rapid Aneurysm, Rapid PE, Rapid Aortic, Rapid CT Stroke, Navigator Pro, Lumina 3D, AngioFlow, Rapid Insights, and the Rapid Mobile App — deployed via the Rapid Edge Cloud infrastructure. The technology processes CT and MRI imaging using proprietary algorithms and biomarkers such as the Hypoperfusion Intensity Ratio (HIR) and CBV Index to support patient selection for thrombectomy and thrombolysis, automated detection of hemorrhages and vessel occlusions, volumetric aneurysm monitoring, pulmonary embolism triage, and 3D vascular reconstruction, with claimed sensitivity/specificity metrics such as 97.84% sensitivity and 99.52% specificity for ICH detection and 94% sensitivity and 93% specificity for PE detection. The platform originated at Stanford University in 2008 and underpinned landmark stroke trials (DAWN, DEFUSE 3, SWIFT-PRIME, EXTEND-IA) that expanded the standard-of-care treatment window from 6 to 24 hours, and is cited as being backed by 750+ clinical publications, 11 NEJM papers, and 25+ clinical trials.

RapidAI monetizes its software through enterprise SaaS / Software-as-a-Medical-Device (SaMD) licensing sold via direct field sales to hospitals and health systems, with quote-based annual subscription pricing that is not publicly disclosed. It serves 2,500+ hospitals across 100+ countries, with named customers spanning the largest US health systems (HCA, Ascension, CommonSpirit, Providence, Trinity, Intermountain, Corewell, Tenet/Atrium) and academic medical centers (Cleveland Clinic, Stanford, Mayo Clinic, Johns Hopkins, UChicago Medicine), as well as international sites (Russells Hall, UK; India deployments). Reported clinical workflow outcomes include 33-52 minute reductions in door-to-treatment times for stroke, 92% reduction in unnecessary transfers, and customer-reported financial gains such as $2.6M in clinical AI value at OSF HealthCare. The company is HQ'd in San Mateo, California (data privacy office in Golden, CO), employs 101-250 staff, and is led by CEO Karim Karti (formerly President & CEO of GE Healthcare Imaging) with co-founders Greg Albers, MD (Stanford Stroke Center) and Roland Bammer, PhD (Stanford 3D Lab) on the scientific side.

The company has raised roughly $100M+ across disclosed funding activity, led by a $75M Series C from Vista Credit Partners in July 2023 with participation from TCV and Lennertz & Co. In 2025 it accelerated product velocity — launching Lumina 3D (TIME Best Inventions 2025), receiving five new FDA clearances (Rapid DeltaFuse, Rapid LMVO, Rapid MLS, Rapid OH, Rapid Aortic), expanding its AWS partnership for global scaling of Rapid Edge Cloud, and announcing 28 ISC 2026 scientific abstracts. Earlier strategic moves included the June 2020 acquisition of EndoVantage (terms undisclosed) and the 2022 introduction of the first Edge Cloud platform and non-contrast CT imaging for ischemic stroke.

Short descriptiontext

RapidAI is a privately held clinical AI company that develops FDA-cleared imaging software used by 2,500+ hospitals across 100+ countries to detect strokes, aneurysms, hemorrhages, pulmonary embolisms, and aortic disease, and to accelerate treatment decisions in time-critical neurovascular and cardiovascular care.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSan Mateo, United States
HQ citystring
San Mateo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical AI imaging, stroke detection software, medical imaging analysis, neurovascular AI platform, radiology workflow software
Industry2 codes
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
NAICS code1 code
  • Software Publishers513210
SIC code2 codes
  • Services-Prepackaged Software7372
  • Surgical & Medical Instruments & Apparatus3841
Product category
Clinical AI Imaging Software
Revenue model1 record
1Software as a Medical Device (SaMD)
TypeSubscription Recurring
Description

Enterprise software licensing model for hospitals and healthcare systems. The platform is deployed across hospital networks with FDA-cleared imaging modules. Revenue generated through software licensing, implementation services, and ongoing support contracts with health systems.

rapidai.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Enterprise platform licensing
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based pricing for enterprise hospital systems. Not publicly disclosed.

rapidai.com
Offering typeSoftware
Software
Brand1 of 15 records shown
1Rapid Enterprise Platform
Description

The cross-disciplinary deployment platform for deep clinical AI enabling disease state decision support across healthcare networks.

rapidai.com
+14 more records
Core offering1 text field

RapidAI develops and sells a deep clinical AI platform (Rapid Enterprise Platform) that processes CT, MRI, and CTA medical imaging to support clinical decision-making for stroke, aneurysm, pulmonary embolism, aortic disease, and radiology workflows. The platform consists of 30 FDA-cleared imaging modules licensed to hospitals and health systems under enterprise SaaS subscriptions, with implementation, support, and ongoing clinical services bundled into multi-year contracts.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 16 values shown
  • 92% reduction in unnecessary transfers
+15 more records
Product overview1 text field

RapidAI offers a comprehensive deep clinical AI platform called the Rapid Enterprise Platform, which includes multiple FDA-cleared imaging modules and solutions for neurovascular, cardiac, and radiology care. The portfolio centers on the core platform augmented by specialized products including Lumina 3D (3D imaging reconstruction), Rapid Aneurysm (cerebral aneurysm detection), Rapid PE (pulmonary embolism), Rapid Aortic (aortic disease), Rapid LVO/LMVO (vessel occlusion detection), Rapid CT Stroke (ischemic stroke), Rapid ICH (hemorrhage detection), Navigator Pro (radiology workflow), Rapid Insights (analytics), and the Rapid Mobile App. The platform is powered by Rapid Edge Cloud infrastructure and supports 2,250+ hospitals across 100+ countries with 30 FDA-cleared modules.

Product and service18 records
1Rapid Enterprise Platform
CategoryEnterprise AI Platform
Description

Cross-disciplinary enterprise AI platform that connects intelligence, workflow, and teams across health systems, enabling deployment of deep clinical AI decision support across multiple disease states for hospitals and hospital networks.

2Lumina 3D
Category3D Vascular Imaging
Description

AI-driven 3D imaging solution that automatically generates detailed 3D vascular views of the brain and neck from CT scans with vessel segmentation and automated bone removal, designed for radiologists and stroke care teams.

3Rapid Aneurysm
CategoryAneurysm Detection
Description

AI-powered platform for cerebral aneurysm detection, volumetric measurement, and longitudinal monitoring, used by neurovascular and neurosurgery teams to detect clinically significant growth missed by traditional 2D methods.

4Rapid PE
CategoryPulmonary Embolism
Description

Pulmonary embolism AI solution for triage, RV/LV ratio assessment, and incidental PE detection, helping cardiology and pulmonary embolism teams identify treatment-eligible patients and coordinate care.

5Rapid Aortic
CategoryAortic Disease
Description

FDA-cleared AI solution for aortic disease assessment and management that automatically analyzes CT scans, generates zonal maximums and landmark measurements, and supports longitudinal monitoring of aortic patients.

6Rapid LVO
CategoryStroke Detection
Description

AI module for automated detection of large vessel occlusions (ICA, MCA) on CT angiography with high sensitivity and negative predictive value, used by stroke teams for rapid LVO identification.

7Rapid LMVO
CategoryStroke Detection
Description

FDA-cleared imaging module that detects suspected vessel occlusions across ICA, MCA, ACA, Basilar, and PCA, providing complete visibility into vascular pathology beyond LVO-only detection.

8Rapid MLS
CategoryStroke Detection
Description

FDA-cleared imaging module expanding clinical AI capabilities for stroke and brain injury diagnosis and treatment.

9Rapid OH
CategoryBrain Injury
Description

FDA-cleared imaging module for detection and management of brain injury conditions including hydrocephalus.

10Rapid DeltaFuse
CategoryStroke Detection
Description

FDA-cleared imaging module enhancing the Rapid Enterprise Platform with advanced clinical AI for improved decision-making and patient management.

11Rapid ICH
CategoryHemorrhagic Stroke
Description

AI-driven intracranial hemorrhage detection module with high sensitivity and specificity, used by radiology and stroke teams for automated cerebral hemorrhage identification.

12Rapid CTP
CategoryCT Perfusion Analysis
Description

CT perfusion analysis software using advanced biomarkers such as Hypoperfusion Intensity Ratio (HIR) and CBV Index for predicting collateral status and infarct growth, used for patient selection in thrombectomy and thrombolysis.

13Rapid CT Stroke
CategoryStroke Detection
Description

Non-contrast CT imaging platform for ischemic stroke detection and assessment.

14Navigator Pro
CategoryRadiology Workflow
Description

Imaging prioritization and AI decision support tool for radiology departments that helps triage and prioritize imaging worklists.

15Rapid Insights
CategoryAnalytics
Description

Custom performance analytics platform enabling tracking and analysis of imaging metrics, patient data, and operational efficiency for care teams.

16Rapid Mobile App
CategoryMobile Workflow
Description

Mobile application providing real-time collaboration, alerts for urgent cases, DICOM viewer access, team coordination, and EMR integration.

17Rapid Edge Cloud
CategoryEnterprise Infrastructure
Description

Enterprise infrastructure platform delivering speed, resilience, and security for AI deployment across the Rapid Enterprise Platform, supporting hospitals in over 100 countries through edge computing capabilities.

18AngioFlow
CategoryStroke Workflow
Description

AI-powered imaging solution for stroke care workflow optimization, deployed by hospital systems such as St. Luke's University Health Network.

Scale indicator28 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-12-01
Description

Expanded partnership to accelerate global deployment and scalability of deep clinical AI in healthcare. Combines AWS's AI infrastructure and machine learning pipelines with RapidAI's deep clinical expertise and multimodal healthcare data. Rapid Edge Cloud platform currently supports hospitals in over 100 countries. Focus on co-development of advanced AI solutions to improve diagnostic precision, streamline clinical workflows, and expand access to life-saving technologies worldwide.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration across 190 stroke centers demonstrating the clinical and operational value of RapidAI's FDA-cleared deep clinical AI platform. Partnership supports real-world evidence generation and workflow optimization across the stroke care continuum.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-founder Dr. Greg Albers serves as Director of Stanford Stroke Center since 1992. Research collaboration led to landmark trials (DAWN, DEFUSE 3) that changed global stroke guidelines. Stanford 3D Lab co-directed by co-founder Roland Bammer. Ongoing clinical validation partnership supporting publication of clinical evidence.

4NIH StrokeNet
Strategic tierCoreTypeStrategic or Co-development Partner
Description

RapidAI serves as exclusive imaging vendor for SISTER Trial (Phase 2, prospective, randomized, placebo-controlled trial for TS23). Also used for patient selection in HI-PEITHO trial for pulmonary embolism treatment.

businesswire.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Viz.ai is the most direct competitor to RapidAI, offering AI-powered LVO/stroke detection, care coordination, and an enterprise platform deployed at hospitals. RapidAI explicitly benchmarks its Rapid LVO product against Viz LVO, underscoring head-to-head overlap in stroke imaging AI.

TypeDirect peer
Description

Aidoc provides a broad AI imaging platform covering multiple pathologies (including stroke and PE) deployed at hospital systems. It competes directly with RapidAI's enterprise imaging AI strategy and cross-disease module approach.

3Avicenna.AI
TypeEmerging player
Description

Avicenna.AI develops AI tools for emergency and neurovascular imaging, including stroke and PE detection workflows. It competes in the same hospital radiology and acute-care AI budgets as RapidAI but with a narrower product set.

TypeEmerging player
Description

Annalise.ai offers comprehensive radiology AI covering chest, brain, and musculoskeletal imaging, competing for the same enterprise radiology decision-support budgets that RapidAI's Navigator Pro and Lumina 3D target.

TypeDirect peer
Description

Brainomix provides AI-based stroke imaging assessment (e.g., e-ASPECTS), directly competing with RapidAI's CT perfusion and stroke triage modules in neurovascular workflows across US and European hospitals.

TypeBroad incumbent
Description

GE Healthcare is the broad incumbent from which RapidAI's CEO (Karim Karti) and CTO (Amit Phadnis, creator of Edison) hail. Its Edison platform and native AI capabilities across imaging modalities compete with RapidAI's enterprise platform, especially at IDN customers that already standardize on GE.

TypeBroad incumbent
Description

Siemens Healthineers offers AI-Rad Companion and digital health solutions across its imaging equipment installed base. It competes with RapidAI by bundling AI capabilities into modality and PACS purchases rather than as a standalone enterprise software contract.

TypeBroad incumbent
Description

Philips provides IntelliSpace AI and enterprise imaging informatics, competing with RapidAI's Rapid Enterprise Platform and Navigator Pro at hospitals standardizing on Philips PACS/RIS and modality infrastructure.

TypeOthers
Description

RapidAI is itself the rebranded iSchemaView, the original developer of the RAPID perfusion platform; included here as a historical reference rather than a separate peer.

10Nanox (Zebra Medical Vision)
TypeEmerging player
Description

Nanox, which acquired Zebra Medical Vision, offers AI imaging analytics across multiple disease states and competes with RapidAI for hospital imaging AI contracts, particularly in cross-disease enterprise deployments.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers30 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature11 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RapidAI

Clinical AI Imaging Softwarerapidai.com

RapidAI is a privately held clinical AI company that develops FDA-cleared imaging software used by 2,500+ hospitals across 100+ countries to detect strokes, aneurysms, hemorrhages, pulmonary embolisms, and aortic disease, and to accelerate treatment decisions in time-critical neurovascular and cardiovascular care.

What RapidAI does

RapidAI (legal entity iSchemaView, Inc.) is a privately held clinical AI company that develops FDA-cleared imaging software for stroke, neurovascular, and cardiovascular care. Its Rapid Enterprise Platform bundles 30 cleared modules — including Rapid CTP, Rapid LVO/LMVO, Rapid ICH, Rapid Aneurysm, Rapid PE, Rapid Aortic, Rapid CT Stroke, Navigator Pro, Lumina 3D, AngioFlow, Rapid Insights, and the Rapid Mobile App — deployed via the Rapid Edge Cloud infrastructure. The technology processes CT and MRI imaging using proprietary algorithms and biomarkers such as the Hypoperfusion Intensity Ratio (HIR) and CBV Index to support patient selection for thrombectomy and thrombolysis, automated detection of hemorrhages and vessel occlusions, volumetric aneurysm monitoring, pulmonary embolism triage, and 3D vascular reconstruction, with claimed sensitivity/specificity metrics such as 97.84% sensitivity and 99.52% specificity for ICH detection and 94% sensitivity and 93% specificity for PE detection. The platform originated at Stanford University in 2008 and underpinned landmark stroke trials (DAWN, DEFUSE 3, SWIFT-PRIME, EXTEND-IA) that expanded the standard-of-care treatment window from 6 to 24 hours, and is cited as being backed by 750+ clinical publications, 11 NEJM papers, and 25+ clinical trials.

RapidAI monetizes its software through enterprise SaaS / Software-as-a-Medical-Device (SaMD) licensing sold via direct field sales to hospitals and health systems, with quote-based annual subscription pricing that is not publicly disclosed. It serves 2,500+ hospitals across 100+ countries, with named customers spanning the largest US health systems (HCA, Ascension, CommonSpirit, Providence, Trinity, Intermountain, Corewell, Tenet/Atrium) and academic medical centers (Cleveland Clinic, Stanford, Mayo Clinic, Johns Hopkins, UChicago Medicine), as well as international sites (Russells Hall, UK; India deployments). Reported clinical workflow outcomes include 33-52 minute reductions in door-to-treatment times for stroke, 92% reduction in unnecessary transfers, and customer-reported financial gains such as $2.6M in clinical AI value at OSF HealthCare. The company is HQ'd in San Mateo, California (data privacy office in Golden, CO), employs 101-250 staff, and is led by CEO Karim Karti (formerly President & CEO of GE Healthcare Imaging) with co-founders Greg Albers, MD (Stanford Stroke Center) and Roland Bammer, PhD (Stanford 3D Lab) on the scientific side.

The company has raised roughly $100M+ across disclosed funding activity, led by a $75M Series C from Vista Credit Partners in July 2023 with participation from TCV and Lennertz & Co. In 2025 it accelerated product velocity — launching Lumina 3D (TIME Best Inventions 2025), receiving five new FDA clearances (Rapid DeltaFuse, Rapid LMVO, Rapid MLS, Rapid OH, Rapid Aortic), expanding its AWS partnership for global scaling of Rapid Edge Cloud, and announcing 28 ISC 2026 scientific abstracts. Earlier strategic moves included the June 2020 acquisition of EndoVantage (terms undisclosed) and the 2022 introduction of the first Edge Cloud platform and non-contrast CT imaging for ischemic stroke.

RapidAI firmographics

Firmographics
Name
RapidAI
Legal name
iSchemaView, Inc.
Website
https://rapidai.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
51–100 employees
Short description
RapidAI is a privately held clinical AI company that develops FDA-cleared imaging software used by 2,500+ hospitals across 100+ countries to detect strokes, aneurysms, hemorrhages, pulmonary embolisms, and aortic disease, and to accelerate treatment decisions in time-critical neurovascular and cardiovascular care.
Ownership category
akta.pro rank

RapidAI industry classification

Industry
Product category
Clinical AI Imaging Software
NAICS
Software Publishers (513210)
SIC
Services-Prepackaged Software (7372), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT

Keywords

  • Clinical AI imaging
  • Stroke detection software
  • Medical imaging analysis
  • Neurovascular AI platform
  • Radiology workflow software

Where RapidAI is headquartered

Location

Headquarters

HQ city
San Mateo
HQ country
United States
HQ region
North America

Offices2 records

Markets served

RapidAI business model

Business model
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Software as a Medical Device (SaMD): Enterprise software licensing model for hospitals and healthcare systems. The platform is deployed across hospital networks with FDA-cleared imaging modules. Revenue generated through software licensing, implementation services, and ongoing support contracts with health systems.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise platform licensing

Distribution channels2 records

Marketing channels8 records

RapidAI product offering

Product offering

Core offering

RapidAI develops and sells a deep clinical AI platform (Rapid Enterprise Platform) that processes CT, MRI, and CTA medical imaging to support clinical decision-making for stroke, aneurysm, pulmonary embolism, aortic disease, and radiology workflows. The platform consists of 30 FDA-cleared imaging modules licensed to hospitals and health systems under enterprise SaaS subscriptions, with implementation, support, and ongoing clinical services bundled into multi-year contracts.

Product overview

RapidAI offers a comprehensive deep clinical AI platform called the Rapid Enterprise Platform, which includes multiple FDA-cleared imaging modules and solutions for neurovascular, cardiac, and radiology care. The portfolio centers on the core platform augmented by specialized products including Lumina 3D (3D imaging reconstruction), Rapid Aneurysm (cerebral aneurysm detection), Rapid PE (pulmonary embolism), Rapid Aortic (aortic disease), Rapid LVO/LMVO (vessel occlusion detection), Rapid CT Stroke (ischemic stroke), Rapid ICH (hemorrhage detection), Navigator Pro (radiology workflow), Rapid Insights (analytics), and the Rapid Mobile App. The platform is powered by Rapid Edge Cloud infrastructure and supports 2,250+ hospitals across 100+ countries with 30 FDA-cleared modules.

Differentiator

Problem solved

Functional benefit

Brands

  • Rapid Enterprise Platform: The cross-disciplinary deployment platform for deep clinical AI enabling disease state decision support across healthcare networks.
  • Navigator Pro
  • Lumina 3D
  • Rapid Edge Cloud
  • Rapid Mobile App
  • Rapid Insights
  • AngioFlow by RapidAI
  • Rapid Aortic
  • Rapid PE
  • Rapid ICH
  • Rapid LVO
  • Rapid DeltaFuse
  • Rapid LMVO
  • Rapid MLS
  • Rapid OH

Products and services

  • Rapid Enterprise Platform Cross-disciplinary enterprise AI platform that connects intelligence, workflow, and teams across health systems, enabling deployment of deep clinical AI decision support across multiple disease states for hospitals and hospital networks.
  • Lumina 3D AI-driven 3D imaging solution that automatically generates detailed 3D vascular views of the brain and neck from CT scans with vessel segmentation and automated bone removal, designed for radiologists and stroke care teams.
  • Rapid Aneurysm AI-powered platform for cerebral aneurysm detection, volumetric measurement, and longitudinal monitoring, used by neurovascular and neurosurgery teams to detect clinically significant growth missed by traditional 2D methods.
  • Rapid PE Pulmonary embolism AI solution for triage, RV/LV ratio assessment, and incidental PE detection, helping cardiology and pulmonary embolism teams identify treatment-eligible patients and coordinate care.
  • Rapid Aortic FDA-cleared AI solution for aortic disease assessment and management that automatically analyzes CT scans, generates zonal maximums and landmark measurements, and supports longitudinal monitoring of aortic patients.
  • Rapid LVO AI module for automated detection of large vessel occlusions (ICA, MCA) on CT angiography with high sensitivity and negative predictive value, used by stroke teams for rapid LVO identification.
  • Rapid LMVO FDA-cleared imaging module that detects suspected vessel occlusions across ICA, MCA, ACA, Basilar, and PCA, providing complete visibility into vascular pathology beyond LVO-only detection.
  • Rapid MLS FDA-cleared imaging module expanding clinical AI capabilities for stroke and brain injury diagnosis and treatment.
  • Rapid OH FDA-cleared imaging module for detection and management of brain injury conditions including hydrocephalus.
  • Rapid DeltaFuse FDA-cleared imaging module enhancing the Rapid Enterprise Platform with advanced clinical AI for improved decision-making and patient management.
  • Rapid ICH AI-driven intracranial hemorrhage detection module with high sensitivity and specificity, used by radiology and stroke teams for automated cerebral hemorrhage identification.
  • Rapid CTP CT perfusion analysis software using advanced biomarkers such as Hypoperfusion Intensity Ratio (HIR) and CBV Index for predicting collateral status and infarct growth, used for patient selection in thrombectomy and thrombolysis.
  • Rapid CT Stroke Non-contrast CT imaging platform for ischemic stroke detection and assessment.
  • Navigator Pro Imaging prioritization and AI decision support tool for radiology departments that helps triage and prioritize imaging worklists.
  • Rapid Insights Custom performance analytics platform enabling tracking and analysis of imaging metrics, patient data, and operational efficiency for care teams.
  • Rapid Mobile App Mobile application providing real-time collaboration, alerts for urgent cases, DICOM viewer access, team coordination, and EMR integration.
  • Rapid Edge Cloud Enterprise infrastructure platform delivering speed, resilience, and security for AI deployment across the Rapid Enterprise Platform, supporting hospitals in over 100 countries through edge computing capabilities.
  • AngioFlow AI-powered imaging solution for stroke care workflow optimization, deployed by hospital systems such as St. Luke's University Health Network.

Quantifiable outcome

  • 92% reduction in unnecessary transfers
  • +15 more outcomes

Companies that use RapidAI

Customer profile

Named customers30 records

Segments6 records

Ideal customer profiles3 records

RapidAI technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability7 records

Feature11 records

RapidAI partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Amazon Web Services (AWS)coreTechnology or Integration · 1 December 2025Expanded partnership to accelerate global deployment and scalability of deep clinical AI in healthcare. Combines AWS's AI infrastructure and machine learning pipelines with RapidAI's deep clinical expertise and multimodal healthcare data. Rapid Edge Cloud platform currently supports hospitals in over 100 countries. Focus on co-development of advanced AI solutions to improve diagnostic precision, streamline clinical workflows, and expand access to life-saving technologies worldwide.
  • Florida Stroke RegistrycoreStrategic or Co-development PartnerCollaboration across 190 stroke centers demonstrating the clinical and operational value of RapidAI's FDA-cleared deep clinical AI platform. Partnership supports real-world evidence generation and workflow optimization across the stroke care continuum.
  • Stanford Stroke CentercoreStrategic or Co-development PartnerCo-founder Dr. Greg Albers serves as Director of Stanford Stroke Center since 1992. Research collaboration led to landmark trials (DAWN, DEFUSE 3) that changed global stroke guidelines. Stanford 3D Lab co-directed by co-founder Roland Bammer. Ongoing clinical validation partnership supporting publication of clinical evidence.
  • NIH StrokeNetcoreStrategic or Co-development PartnerRapidAI serves as exclusive imaging vendor for SISTER Trial (Phase 2, prospective, randomized, placebo-controlled trial for TS23). Also used for patient selection in HI-PEITHO trial for pulmonary embolism treatment.

Scale indicators28 records

Recent moves7 records

Expansion highlights6 records

RapidAI competitors and assessment

Company assessment

Direct peers

  • Viz.ai: Viz.ai is the most direct competitor to RapidAI, offering AI-powered LVO/stroke detection, care coordination, and an enterprise platform deployed at hospitals. RapidAI explicitly benchmarks its Rapid LVO product against Viz LVO, underscoring head-to-head overlap in stroke imaging AI.
  • Aidoc: Aidoc provides a broad AI imaging platform covering multiple pathologies (including stroke and PE) deployed at hospital systems. It competes directly with RapidAI's enterprise imaging AI strategy and cross-disease module approach.
  • Brainomix: Brainomix provides AI-based stroke imaging assessment (e.g., e-ASPECTS), directly competing with RapidAI's CT perfusion and stroke triage modules in neurovascular workflows across US and European hospitals.

Emerging players

  • Avicenna.AI: Avicenna.AI develops AI tools for emergency and neurovascular imaging, including stroke and PE detection workflows. It competes in the same hospital radiology and acute-care AI budgets as RapidAI but with a narrower product set.
  • Annalise.ai: Annalise.ai offers comprehensive radiology AI covering chest, brain, and musculoskeletal imaging, competing for the same enterprise radiology decision-support budgets that RapidAI's Navigator Pro and Lumina 3D target.
  • Nanox (Zebra Medical Vision): Nanox, which acquired Zebra Medical Vision, offers AI imaging analytics across multiple disease states and competes with RapidAI for hospital imaging AI contracts, particularly in cross-disease enterprise deployments.

Broad incumbents

  • GE Healthcare: GE Healthcare is the broad incumbent from which RapidAI's CEO (Karim Karti) and CTO (Amit Phadnis, creator of Edison) hail. Its Edison platform and native AI capabilities across imaging modalities compete with RapidAI's enterprise platform, especially at IDN customers that already standardize on GE.
  • Siemens Healthineers: Siemens Healthineers offers AI-Rad Companion and digital health solutions across its imaging equipment installed base. It competes with RapidAI by bundling AI capabilities into modality and PACS purchases rather than as a standalone enterprise software contract.
  • Philips: Philips provides IntelliSpace AI and enterprise imaging informatics, competing with RapidAI's Rapid Enterprise Platform and Navigator Pro at hospitals standardizing on Philips PACS/RIS and modality infrastructure.

Others

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

RapidAI social profiles

Digital presence

RapidAI compliance and trust

Trust signal

Compliance2 records

RapidAI financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RapidAI leadership team

Management profile

Number of profiles

Profiles15 records

RapidAI funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RapidAI M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RapidAI

What does RapidAI do?

RapidAI develops and sells a deep clinical AI platform (Rapid Enterprise Platform) that processes CT, MRI, and CTA medical imaging to support clinical decision-making for stroke, aneurysm, pulmonary embolism, aortic disease, and radiology workflows. The platform consists of 30 FDA-cleared imaging modules licensed to hospitals and health systems under enterprise SaaS subscriptions, with implementation, support, and ongoing clinical services bundled into multi-year contracts.

Is RapidAI a public or private company?

RapidAI is a private company. It is classified as venture growth investor backed and is currently operating.

When was RapidAI founded?

RapidAI was founded in 2008. It employs 51 to 100 people.

Where is RapidAI based?

RapidAI is headquartered in San Mateo, United States, in the North America region.

How does RapidAI make money?

One revenue line is on record: software as a Medical Device (SaMD).

Who are RapidAI's main competitors?

Direct peers on record are Viz.ai, Aidoc and Brainomix. Emerging players are Avicenna.AI, Annalise.ai and Nanox (Zebra Medical Vision). Broad incumbents are GE Healthcare, Siemens Healthineers and Philips. iSchemaView (acquired by RapidAI legacy entity) is listed as an others.

Does RapidAI have an API?

No public API is recorded for RapidAI.

What industry is RapidAI in?

RapidAI's product category is Clinical AI Imaging Software. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage). Its NAICS code is 513210 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Imaging Technology NewsNeurophet, RapidAI Team Up to Expand Access to Alzheimer’s, MS Treatment MonitoringNeurophet and RapidAI partnered to integrate Neurophet's brain imaging solutions into the Rapid Enterprise Platform, accelerating U.S. commercialization. The integration includes Neurophet AQUA AD Plus and SCALE PET for Alzheimer's monitoring and AQUA MS for multiple sclerosis. Full-scale distribution will target U.S. memory disorder centers prescribing Leqembi and Kisunla.YahooNeurophet and RapidAI Partner to Expand Access to Alzheimer's and MS Treatment MonitoringNeurophet and RapidAI announced a partnership to integrate Neurophet's brain imaging solutions into RapidAI's enterprise platform, expanding access in the U.S. market. The integration targets Alzheimer's and MS treatment monitoring, with full-scale distribution planned for memory disorder centers prescribing Leqembi and Kisunla.PR Newswire APACNeurophet and RapidAI Partner to Expand Access to Alzheimer's and MS Treatment MonitoringNeurophet and RapidAI announced a partnership to integrate Neurophet's brain imaging solutions into RapidAI's enterprise platform, targeting U.S. Alzheimer's and MS treatment monitoring. The integration includes Neurophet AQUA AD Plus and AQUA MS, with plans to begin full-scale distribution in U.S. memory disorder centers. The companies aim to expand access to advanced neuroimaging through RapidAI's hospital network.PR NewswireNeurophet and RapidAI Partner to Expand Access to Alzheimer's and MS Treatment MonitoringNeurophet and RapidAI announced a partnership to integrate Neurophet's brain imaging solutions into RapidAI's enterprise platform, expanding access to Alzheimer's and MS treatment monitoring. The integration targets U.S. hospitals, with full-scale distribution planned for memory disorders centers prescribing Leqembi and Kisunla. The companies aim to expand platform integration to cover the entire dementia care continuum.Imaging Technology NewsAZ Med X-ray AI Applications Now Available on RapidAI’s Enterprise PlatformAZmed announced its FDA-cleared AZtrauma and AZchest X-ray AI applications are now available on RapidAI's Enterprise Platform. The apps join over 50 clinical solutions used by more than 2,500 hospitals, with AZtrauma detecting fractures and AZchest covering five chest findings. The integration aims to streamline access to AI findings across clinical specialties.Imaging Technology NewsOptellum’s Virtual Nodule Clinic Now Available on RapidAI’s Enterprise PlatformOptellum integrated its Virtual Nodule Clinic with RapidAI's Enterprise Platform, expanding lung nodule AI access. The FDA-cleared, Medicare-reimbursed solution has analyzed over 3 million cases. Integration aims to accelerate deployment across health systems using RapidAI.Pulse 2.0Riverain Technologies Expands ClearRead Chest AI Access Through RapidAI Enterprise PlatformRiverain Technologies is integrating its FDA-cleared ClearRead Chest cardiothoracic AI suite into RapidAI's Rapid Enterprise Platform, extending lung and cardiac imaging to an enterprise environment. The integration will be available to RapidAI's installed base of over 2,500 hospitals, aiming to reduce radiologist cognitive burden and support earlier detection of lung cancer and cardiovascular disease.Digital Health NewsRapidAI Introduces EdgeIQ to Orchestrate Imaging AI WorkflowsRapidAI introduced EdgeIQ, an imaging orchestrator that automates study identification, prioritization, and routing across AI workflows. It uses DICOM metadata and pixel data, operates continuously from acquisition, and supports both positive and negative findings. The system aims to reduce manual protocol mapping and unprocessed exams as AI portfolios expand.Pulse 2.0RapidAI Launches EdgeIQ To Orchestrate Imaging AI Workflows Across Health SystemsRapidAI launched EdgeIQ, an imaging orchestration system that automates matching medical imaging studies with AI models across health systems. It uses DICOM metadata and pixel data to route series to appropriate AI modules, respecting scanner-level priorities and supporting third-party algorithms. The platform aims to reduce manual configuration and operational burden.Digital Health NewsRapidAI, Gravity MedTech Partner to Advance Connected Neurovascular Care in IndiaRapidAI and Gravity MedTech partnered to integrate AI-powered stroke imaging with mechanical thrombectomy devices in India, aiming to reduce delays between diagnosis and intervention. The collaboration will incorporate RapidAI software into Gravity MedTech's GRASSROOT Registry to generate real-world evidence on AI-enabled stroke workflows.